San Mateo, Calif. – February 13, 2023 — MORE Health, a global digital health company, announces today that it will participate virtually in BTIG at Snowbird: Medtech, Digital Health, Life Science & Diagnostic Tools Conference, from February 14-16, 2023, in Snowbird, Utah.
The conference brings together industry leaders to explore emerging innovations and trends across the healthcare industry. Attendees will include over 75 corporate management teams from life science and digital health organizations. MORE Health is attending to discuss its innovative solutions in critical illness with potential strategic partners, equity analysts, and investors.
“MORE Health is improving health outcomes globally through patient advocacy services designed to help people with critical illnesses. Using our digital solutions, we provide access to the best medical minds in the world and high-touch services to ensure patients have the right diagnosis and treatment path,” said William Wen, Corporate Development and Investor Relations at MORE Health. “In doing this, we create unique patient acquisition opportunities for leading hospital systems worldwide. We also help life science organizations conduct clinical trials through our patient recruitment activities and provide focused data to assist researchers with drug development.”
About MORE Health®
MOREHealth is a global digital health company known for giving individuals access to the best medical minds when facing a serious illness. Recognized as a leader in cross-border telemedicine, MORE Health brings renowned specialists together through its award-winning technology, connecting them with patients worldwide. To date, MORE Health has helped patients on six continents and continues its mission to provide clients and their members access to the best medical minds in the world—when they need it most. The company, incorporated in 2013, is headquartered in Silicon Valley. For more information, visit morehealth.com.
Follow MORE Health on LinkedIn, Facebook, Twitter, and Instagram. For media or investor inquiries, please contact us.
